Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies

Cancer Causes and Control

Volumn 23, Issue 5, 2012, Pages 779-784

  Faupel Badger, Jessica M ^a   Wang, Yuping ^b   Staff, Anne Cathrine ^c,d   Karumanchi, S Ananth ^e   Stanczyk, Frank Z ^f   Pollak, Michael ^g   Hoover, Robert N ^a   Troisi, Rebecca ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

African American; IGF; Leptin; Preeclampsia; Prolactin; sFlt 1

Indexed keywords

ANDROSTENEDIONE; ANGIOGENIC FACTOR; PROLACTIN; SEX HORMONE; SOLUBLE ENDOGLIN; SOLUBLE FMS-LIKE TYROSINE KINASE 1; SOMATOMEDIN; STEROID SEX HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; CASE CONTROL STUDY; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GESTATIONAL AGE; HORMONE BLOOD LEVEL; HUMAN; MATERNAL AGE; MATERNAL BLOOD; POPULATION RESEARCH; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; UMBILICAL CORD BLOOD;

ADOLESCENT; ADULT; AFRICAN AMERICANS; ANGIOGENIC PROTEINS; CASE-CONTROL STUDIES; FEMALE; FETAL BLOOD; GONADAL STEROID HORMONES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEOVASCULARIZATION, PHYSIOLOGIC; PRE-ECLAMPSIA; PREGNANCY; PROLACTIN; SOMATOMEDINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84862815195     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-012-9934-9     Document Type: Article

References (41)

1. Bellamy L, Casas JP, Hingorani AD, Williams DJ (2007) Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 335:974
2. Craici I, Wagner S, Garovic VD (2008) Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther Adv Cardiovasc Dis 2:249-259
3. Powe CE, Levine RJ, Karumanchi SA (2011) Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123:2856-2869
4. Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJ (2009) Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort study. Stroke 40:1176-1180
5. Tenhola S, Rahiala E, Halonen P, Vanninen E, Voutilainen R (2006) Maternal preeclampsia predicts elevated blood pressure in 12-year-old children: evaluation by ambulatory blood pressure monitoring. Pediatr Res 59:320-324 (Pubitemid 43841010)
6. Innes KE, Byers TE (1999) Preeclampsia and breast cancer risk. Epidemiology 10:722-732 (Pubitemid 29494054)
7. Troisi R, Potischman N, Hoover RN (2007) Exploring the underlying hormonal mechanisms of prenatal risk factors for breast cancer: a review and commentary. Cancer Epidemiol Biomarkers Prev 16:1700-1712 (Pubitemid 47450497)
8. Acromite MT, Mantzoros CS, Leach RE, Hurwitz J, Dorey LG (1999) Androgens in preeclampsia. Am J Obstet Gynecol 180:60-63 (Pubitemid 29088390)
9. Young BC, Levine RJ, Karumanchi SA (2010) Pathogenesis of preeclampsia. Annu Rev Pathol 5:173-192
10. Gingery A, Bahe EL, Gilbert JS (2009) Placental ischemia and breast cancer risk after preeclampsia: tying the knot. Expert Rev Anticancer Ther 9:671-681
11. Key T, Appleby P, Barnes I, Reeves G (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606-616 (Pubitemid 34498648)
12. Ray A, Cleary MP (2010) Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets 14:443-451
13. Vona-Davis L, Rose DP (2009) Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev 20:193-201
14. Fauser BC, Laven JS, Tarlatzis BC, Moley KH, Critchley HO, Taylor RN et al. (2011) Sex steroid hormones and reproductive disorders: impact on women's health. Reprod Sci 18:702-712
15. Walker JJ (2000) Pre-eclampsia. Lancet 356:1260-1265
16. Wang A, Rana S, Karumanchi SA (2009) Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 24:147-158
17. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP et al (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355:992-1005 (Pubitemid 44343543)
18. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672-683 (Pubitemid 38364626)
19. Levine RJ, Qian C, Maynard SE, Yu KF, Epstein FH, Karumanchi SA (2006) Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol 194:1034-1041
20. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649-658
21. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H et al (2007) Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50:137-142 (Pubitemid 46986022)
22. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H et al (2008) A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 21:9-23
23. Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR (2005) Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 122:33-39 (Pubitemid 41265677)
24. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP et al (2004) First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 89:770-775 (Pubitemid 38269892)
25. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM et al (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12:642-649 (Pubitemid 43865232)
26. Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303:235-241
27. Knuist M, Bonsel GJ, Zondervan HA, Treffers PE (1998) Risk factors for preeclampsia in nulliparous women in distinct ethnic groups: a prospective cohort study. Obstet Gynecol 92:174-178 (Pubitemid 28350843)
28. Tanaka M, Jaamaa G, Kaiser M, Hills E, Soim A, Zhu M et al (2007) Racial disparity in hypertensive disorders of pregnancy in New York State: a 10-year longitudinal population-based study. Am J Public Health 97:163-170 (Pubitemid 46067699)
29. Tucker MJ, Berg CJ, Callaghan WM, Hsia J (2007) The Black- White disparity in pregnancy-related mortality from 5 conditions: differences in prevalence and case-fatality rates. Am J Public Health 97:247-251 (Pubitemid 47279370)
30. Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL (1988) The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer 57:216-218 (Pubitemid 18085409)
31. Salamalekis E, Bakas P, Vitoratos N, Eleptheriadis M, Creatsas G (2006) Androgen levels in the third trimester of pregnancy in patients with preeclampsia. Eur J Obstet Gynecol Reprod Biol 126:16-19
32. Troisi R, Potischman N, Roberts JM, Ness R, Crombleholme W, Lykins D et al (2003) Maternal serum oestrogen and androgen concentrations in preeclamptic and uncomplicated pregnancies. Int J Epidemiol 32:455-460 (Pubitemid 36764107)
33. Zhang J, Masciocchi M, Lewis D, Sun W, Liu A, Wang Y (2008) Placental anti-oxidant gene polymorphisms, enzyme activity, and oxidative stress in preeclampsia. Placenta 29:439-443
34. Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC (2007) Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 196(239):e1-e6
35. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP et al (2008) The change in concentrations of angiogenic and antiangiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 21:279-287 (Pubitemid 351652513)
36. Troisi R, Vatten L, Hoover RN, Roberts JM, Cole BF, Potischman N (2006) Maternal androgen and estrogen concentrations are not associated with blood pressure changes in uncomplicated pregnancies. Cancer Epidemiol Biomarkers Prev 15:2013-2015 (Pubitemid 44664285)
37. Vatten LJ, Odegard RA, Nilsen ST, Salvesen KA, Austgulen R (2002) Relationship of insulin-like growth factor-I and insulinlike growth factor binding proteins in umbilical cord plasma to preeclampsia and infant birth weight. Obstet Gynecol 99:85-90 (Pubitemid 34075474)
38. Xue F, Michels KB (2007) Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. Lancet Oncol 8:1088-1100 (Pubitemid 350192898)
39. Fryar CD, Hirsch R, Eberhardt MS, Yoon SS, Wright JD (2010) Hypertension, high serum total cholesterol, and diabetes: racial and ethnic prevalence differences in U.S. adults, 1999-2006. NCHS Data Brief 1-8
40. Samadi AR, Mayberry RM, Zaidi AA, Pleasant JC, McGhee N Jr, Rice RJ (1996) Maternal hypertension and associated pregnancy complications among African-American and other women in the United States. Obstet Gynecol 87:557-563 (Pubitemid 26102741)
41. Vatten LJ, Forman MR, Nilsen TI, Barrett JC, Romundstad PR (2007) The negative association between pre-eclampsia and breast cancer risk may depend on the offspring's gender. Br J Cancer 96:1436-1438